SLC16A7 and lymphoma: The MCT1 inhibitor AZD3965, combined with an inhibitor of oxidative phosphorylation, induced significant lymphoma cell death in vitro and reduced disease burden in vivo [29], and MCT2 is the predominant MCT in neurons [30].